ABSTRACT
Background Digital adherence technologies (DATs) may provide a patient-centered approach for supporting tuberculosis (TB) medication adherence and improving treatment outcomes. We synthesized evidence addressing costs and cost-effectiveness of DATs to support TB treatment.
Methods A systematic review (PROSPERO-CRD42022313531) identified relevant literature from January 2000-April 2023 in MEDLINE, Embase, CENTRAL, CINAHL, Web of Science along with preprints from medRxiv, Europe PMC and clinicaltrials.gov. Studies with observational, experimental, or quasi-experimental designs (minimum 20 participants) and modelling studies reporting quantitative data on the cost or cost-effectiveness of DATs for TB infection or disease treatment were included. Study characteristics, cost and cost-effectiveness outcomes were extracted.
Results Of 3,619 titles identified by our systematic search, 29 studies met inclusion criteria, of which 9 addressed cost-effectiveness. DATs included SMS reminders, phone-based technologies, digital pillboxes, ingestible sensors, and video observed treatment (VOT). VOT was the most extensively studied (16 studies) and was generally cost saving when compared to healthcare provider directly observed therapy (DOT), particularly when costs to patients were included--though findings were largely from high-income countries. Cost-effectiveness findings were highly variable, ranging from no clinical effect in one study (SMS), to greater effectiveness with concurrent cost savings (VOT) in others. Only 8 studies adequately reported at least 80% of the elements required by CHEERS, a standard reporting checklist for health economic evaluations.
Conclusion DATs may be cost-saving or cost-effective compared to healthcare provider DOT, particularly in high-income settings. However, more data of higher quality are needed, notably in lower- and middle-income countries which have the greatest TB burden.
What is already known on this topic Digital adherence technologies (DATs) can provide a less intrusive, and potentially less resource-intensive way to monitor and support tuberculosis treatment adherence, as compared to traditional direct observation. To date, there is limited information about the cost and cost-effectiveness of these technologies in diverse care settings.
What this study adds Our comprehensive review of available studies shows that some DATs like video-observed therapy can be cost-saving, particularly in higher-income countries, and especially when patient costs are considered.
How this study might affect research, practice or policy While program savings related to some DATS will likely offset their initial costs in higher-income settings, more evidence is needed from lower-income settings where the TB burden is highest. Costing studies should also more rigorously account for all relevant costs, including those to patients.
Competing Interest Statement
Dr. Kevin Schwartzman reports research funding from the Canadian Institutes of Health Research. He has also served as chair of the Data Safety and Monitoring Board for a COVID-19 therapeutic investigated by Laurent Pharmaceuticals.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022313531
Funding Statement
This review was supported by a grant from the Bill and Melinda Gates Foundation (grant INV-038215). The funder had no involvement in the content or preparation of this manuscript, or in the decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
All data generated or analysed during this study are included in this published article and its supplementary information files.
